Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
October 29, 2015Recent updates include the addition of ganaxolone IV formulation to the Marinus Pharmaceuticals development portfolio. The GLP safety, tolerability, and efficacy studies observed in animal models support the advancement of ganaxolone IV into the clinic.
More »
CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
October 27, 2015CoLucid Pharmaceuticals is a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for acute treatment of migraine headaches in adults. Dr. Corrigan will serve as a class II director of the company.
More »
Celator(R) Pharmaceuticals Announces VYXEOS(TM) (CPX-351) Selected As Best Nanomedicine Product
October 27, 2015The objective of the Nanomedicine Award 2015 is to recognize innovative product developments in nanomedicine and to promote these advances, and the field of nanotechnology, within the international biotechnology and pharmaceutical community.
More »